Initially, head and neck cancer affects squamous cells that line the mucosal surfaces and later on spread across adjoining parts such as larynx, pharynx, paranasal sinuses and nasal cavity, oral cavity, and salivary glands. Market Research Future (MRFR)’s study has found out that the global head and neck cancer market is expected to flourish in the forthcoming years reflecting a CAGR of 9.5% during the forecast period (2017 - 2023).
The occurrence of neck and head cancer is quite high. In termsof the patient population, it is the sixth leading cancer worldwide. It has necessitated the development of drugs and treatments, thus, attracting massive inflows of investments for research & development. This, in turn, is anticipated to propel the expansion of the head and neck cancer market over the next couple of years.
The major causes highlighted for head and neck cancer are smoking and drinking addictions. These addictions have become part of the lifestyle which has led to exponential growth in the number of patients. It is anticipated to create huge demand for treatments. It is likely to aid the proliferation of the head and neck cancer market in the years to come.
Request For Sample Report: https://www.marketresearchfuture.com/sample_request/5798
The report suggests a lucrative future trajectory for the market. However, factors such as side effects associated with treatments and high cost are expected to restrict market growth over the assessment period. Also, the lack of penetration of healthcare systems in middle and low-income nations remains an impediment to the growth pace of the head and neck cancer market.
By type, the global head and neck market cancer market has been segmented into laryngeal cancer, lip and oral cavity cancer, pharyngeal cancer, salivary gland cancer, nasopharyngeal cancer, and others.
By diagnosis, the head and neck cancer market has been segmented into bioscopy screening tests, dental diagnosis, blood tests, imaging, and endoscopy. The bioscopy screening tests segment is further sub-segmented into fine needle aspiration biopsy, incisional biopsy, and HPV testing. The blood tests segment has been sub-segmented into total liver function tests, cell count tests, and EBV antibody measurement. The dental diagnosis segment has been sub-segmented into fluorescence visualization, acetic acid rinse method, toluidine blue dye-based method, and brush biopsy. The imaging is sub-segmented into MRI, X-ray, PET/CT, and Barium Swallow test. The endoscopy is further sub-segmented into laryngoscopy, pharyngoscopy, and others.
By treatment type, the global head and neck cancer market has been segmented into surgery, chemotherapy, targeted therapy, radiation therapy, and others. The radiation therapy is further sub-segmented into internal beam radiation and external radiation therapy.
By end-user, the head and neck cancer market has been segmented into hospitals, specialty clinics, and ambulatory surgical centers.
Browse Complete Report: https://www.marketresearchfuture.com/reports/head-and-neck-cancer-market-5798
The global head and neck cancer market is studied across four regions – Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA). Americas houses a huge patient population and is poised to hold the leading share of the market in the foreseeable future. Led by the U.S., the presence of major healthcare leaders in the region is likely to have a positive impact on the growth pattern of the regional head and neck cancer market. Meanwhile, Asia Pacific is found to exhibit a drastic rise in the growth curve striking a comparatively higher CAGR.
The key players profiled in MRFR’s market share analysis are AB Science SA, Acceleron Pharma, Inc., AbbVie Inc., AdDent Inc., Astellas Pharma Inc., ASAHI Roentgen, AstraZeneca Plc., Boston Biomedical, Inc., Bayer AG, Bristol-Myers Squibb Company, Fujifilm Holdings, Carestream, GE Healthcare, Koninklijke Philips N.V., Identafi, NeuSoft, Siemens Healthcare, Shimadzu Corporation, Varian Medical Systems, and Xoran.
In April 2019, Rodeo Therapeutic, a Seattle-based startup, has raised money for the development of tissue repair and regenerative medicines.
In April 2019, BostonGene, a biomedical software startup, has secured USD 50 Mn from NEC Corporation a multinational provider of information technology services and products, for the transformation of cancer treatments leveraging Precision Medicine Analytics.